Trial Profile
GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms Guardian-1
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.
- 15 Oct 2018 Planned End Date changed from 1 Apr 2021 to 10 Apr 2020.
- 15 Oct 2018 Planned primary completion date changed from 1 Apr 2020 to 10 Apr 2020.